JPRN-UMIN000012433已完成未知
Open-label clinical trial to evaluate the safety and efficacy of the investigational devices in total hip arthroplasty. - Open-label clinical trial to evaluate the safety and efficacy of the investigational devices in total hip arthroplasty.
KYOCERA Medical Corporation0 个研究点目标入组 20 人开始时间: 2013年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria having effects on the evaluation of the investigational devices. 1) Patients who had or will have THA or BHA in the opposite hip within 6 months before or after the operation in this clinical trial. 2) Patients who previously had THA or BHA in the opposite hip and it is apparent that prosthesis exhibits loosening. 3) Patients who are difficult to be followed for 6 months after the surgery. 4) Patients who participated clinical trial of another investigational device or drug within 6 months before participating to this clinical trial. 5) Patients who once participated this clinical trial. 6) Patients in unstable clinical conditions or fatal condition. 7) Patients who have clinically serious organ derangement. *Additionally, there are exclusion criteria related to the product characteristics of the investigational devices.
研究者
相似试验
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000004851EUCTR2017-000290-37-GBProvepharm SAS10
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000012871EUCTR2017-000290-37-FRProvepharm SAS10
进行中（未招募）
1 期
Clinical Study of CV-HFD01 tablets as Adjuvant Therapy in patients with Type 2 DM.CTRI/2019/04/018403Climic Health Pvt Ltd
进行中（未招募）
1 期
A Clinical trial of CV-HFT01 tablets as Adjuvant Therapy in patients with hypothyroidismCTRI/2019/04/018564Climic Health Pvt Ltd
进行中（未招募）
1 期
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms.EUCTR2006-004286-33-PLMarinus Pharmceuticals, Inc.54